Panel discussions
International collaboration is a key element of the Swiss innovation landscape. Early support to build bridges between experts from different countries and collaborative international regulatory approval pathways, such as ACCESS and Orbis, result in faster access for patients. In this panel discussion we will share different perspectives and experiences and provide insights into the opportunities created for patients.
Participants: representatives from Swiss small and mid-si
Global Village track: May 5, 15:30 - 16:15, room Verseau
| Name | Position | Institution |
|---|---|---|
| Eveline Trachsel | Head of Medicinal Product Authorisation and Vigilance | Swissmedic, Swiss Agency for Therapeutic Products |
Swissmedic, the Swiss Agency for Therapeutic Products, is the regulatory and supervisory authority for therapeutic products. Swissmedic ensures that the therapeutic products it approves in Switzerland are of impeccable quality, effective and safe. In doing so it makes a significant contribution to safeguarding human and animal health.
